retatrutide phase 3 trial dosing schedule Eli Lilly's clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments I get this question pretty

The fact that patients in this trial continued to lose weight after gastrointestinal adverse effects had subsided suggests that these effects were not the cause of weight loss

The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights

Mayo Clinic (2024) Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: A systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials, Diabetes Care (2025) The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis, Frontiers in Endocrinology (2025) Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study, Diabetes, Obesity and Metabolism (2025) Exploring side effects and discontinuation reasons of glucagonlike-peptide-1 agonist (liraglutide, semaglutide) for weight loss among patients at King Abdulaziz University, Jeddah in 2021 to 2023, Journal of Clinical Medical Research (2025) FDA approves Novo Nordisks oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event, Novo Nordisk (2025) FDAs concerns with unapproved GLP-1 drugs used for weight loss, FDA (2026) Innovative molecules and delivery technologies enabling the future of GLP-1-based therapies, Endocrine Reviews (2026) Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy and Ozempic, Novo Nordisk (2026) Novo Nordisks Wegovy pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America, Novo Nordisk (2026) Pfizers ultra-long-acting injectable GLP-1 RA shows robust and continued weight loss with monthly dosing in phase 2b trial, Pfizer (2026) Price guide, Novo Nordisk Real-world weight loss among patients initiating semaglutide 2.4 mg and enrolled in wegotogether, a digital self-support application, Advances in Therapy (2025) What to know about orforglipron: An investigational oral GLP-1, Eli Lilly and Company (2025) Real-world HbA1c changes among Type 2 diabetes mellitus patients initiating treatment with a 1.0 mg weekly dose of semaglutide for diabetes, Journal of Health Economics and Outcomes Research (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Moore prefers starting with conservative approaches oral options when available and tailoring the choice to the clinical target

Our team offers guidance on nutrition and physical activity, helping you make sustainable changes that enhance your results during the first month and beyond

Remove any air bubbles before injecting